Intermittent claudication
Drug research and approvals for intermittent claudication: what is recruiting, what Health Canada authorized, FDA orphan designations and EU medicines. See every condition.
As of Nov 20, 2026, 29 studies of intermittent claudication are recruiting on ClinicalTrials.gov, and Health Canada has authorized 0 drug trials for it since 2013.
- Recruiting worldwide: 29
- Trials authorized in Canada: 0
- FDA orphan approvals: 0
- EU medicines: 0
- Predictors of Major Adverse Limb Events After Endovascular Iliac Stenting: a Real-world Cohort StudyNCT07672249 · Not reported · I.R.C.C.S Ospedale Galeazzi-Sant'Ambrogio · starts Jun 16, 2026
- Local And Systemic Macrophage Activation in Coronary and Peripheral Artery DiseaseNCT07588295 · Not applicable · Maria Cecilia Hospital · starts Mar 18, 2024
- Observing the Role of Inflammation in Peripheral Artery Disease and Its Impact on Heart and Mobility Health: PANACEA-O.NCT07500610 · Not reported · Cardiology Research UBC · starts Sep 25, 2025
- Presence of Dural Pulsation in Patients Diagnosed With Lumbar Spinal StenosisNCT07233798 · Not reported · Marmara University · starts Dec 7, 2025
- EVERO Drug-coated Balloon (DCB) Randomized TrialNCT07144150 · Not applicable · Cook Research Incorporated · starts Apr 17, 2026
- Improving Mobility After Revascularization in Peripheral Artery DiseaseNCT06686121 · Phase 3 · Northwestern University · starts Aug 4, 2025
- Response to Exercise and Nitric Oxide in PADNCT06657976 · Phase 2 · Northwestern University · starts Jan 23, 2025
- Exercise Training Study of Patients With Claudicatio IntermittensNCT06448390 · Not applicable · Norwegian University of Science and Technology · starts Jan 1, 2024
- Personalised Multicomponent Exercise Programme in Peripheral Arterial DiseaseNCT06410521 · Not applicable · University of Trás-os-Montes and Alto Douro · starts Jun 20, 2025
Phase 3 6
- LovastatinHMG-CoA reductase inhibitor
- Niacin
- MetforminMitochondrial complex I (NADH dehydrogenase) inhibitor
- CaffeineAdenosine receptor antagonist
- Omega-3-ACID ethyl esters
- RifalazilDNA-directed RNA polymerase inhibitor
Phase 2 11
- CilostazolPhosphodiesterase 3A inhibitor
- ClopidogrelPurinergic receptor P2Y12 antagonist
- SapropterinPhenylalanine-4-hydroxylase activator
- SimvastatinHMG-CoA reductase inhibitor
- ZibotentanEndothelin receptor ET-A antagonist
- TirasemtivFast skeletal troponin complex activator
- AtaciguatSoluble guanylate cyclase activator
- K-134Phosphodiesterase 3 inhibitor
- L-citrulline
- NCX-4016
- Emiplacel
Phase 1 or earlier 1
How its trials ended
231 ClinicalTrials.gov studies of the condition, classified by TrialPanorama, partly automatically, so some labels are wrongOf the 56 whose ending is known, 46% met their primary endpoint, 11% missed it and 43% stopped early.
- Completed, result not reported10144%
- Status unknown4319%
- Ongoing3113%
- Met its primary endpoint2611%
- Stopped: other or unclear167%
- Missed its primary endpoint63%
- Stopped: enrollment or feasibility42%
- Stopped: lack of efficacy1<1%
- Stopped: safety1<1%
- Stopped: sponsor or business decision1<1%
- Stopped: funding1<1%
Condition names come from Health Canada's trial database. Orphan designations and EU medicines are matched when their indication names the condition as whole words, so a broader or differently worded indication can be missed. Recruiting counts are live from ClinicalTrials.gov's own condition search, refreshed daily. ClinicalTrials.gov, Health Canada Clinical Trials Database, FDA orphan designations, EMA